ArticleACS chemical neuroscience2016
Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M
Article in ACS chemical neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Synthesis of Azaisoindolinones by Heterogeneous Catalyzed Regioselective Hydrodeoxygenation ofACS sustainable chemistry & engineering · 2025Article
- Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.Clinical drug investigation · 2024Review
- Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.Biomedicines · 2022Review
- mGluCell reports · 2021Article
- Targeting muscarinic receptors to treat schizophrenia.Behavioural brain research · 2021Review
- Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.ACS pharmacology & translational science · 2020Review
- Modulation of arousal and sleep/wake architecture by MNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Biased MScience signaling · 2019Article
- Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.Trends in pharmacological sciences · 2019Review
- The Role of Estrogen in Brain and Cognitive Aging.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Review
- MBiological psychiatry · 2019Article
- Parvalbumin Cell Ablation of NMDA-R1 Leads to Altered Phase, But Not Amplitude, of Gamma-Band Cross-Frequency Coupling.Brain connectivity · 2019Article
- 6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the MACS chemical neuroscience · 2019Article
- Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as MACS chemical neuroscience · 2019Article
- A Novel MACS chemical neuroscience · 2018Article
- PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems.ACS chemical neuroscience · 2018Article
- VU6007477, a Novel MACS medicinal chemistry letters · 2018Article
- Probing the binding site of novel selective positive allosteric modulators at the MBiochemical pharmacology · 2018Article
- MNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- The discovery of VU0486846: steep SAR from a series of MBioorganic & medicinal chemistry letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
Abnormalities in the signaling of the N-methyl-d-aspartate subtype of the glutamate receptor (NMDAR) within cortical and limbic brain regions are thought to underlie many of the complex cognitive and affective symptoms observed in individuals with schizophrenia. The M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.